Overview

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Status:
Completed

Trial end date:
2018-09-10

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Collaborator:

Janssen Biotech, Inc.